Estimating mean QALYs in trial-based cost-effectiveness analysis: The importance of controlling for baseline utility

Health Economics

Volumn 14, Issue 5, 2005, Pages 487-496

  Manca, Andrea ^a   Hawkins, Neil ^a   Sculpher, Mark J ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Area under the curve; QALYs; Regression; Trial based cost effectiveness analysis

Indexed keywords

ABDOMINAL HYSTERECTOMY; ARTICLE; CALCULATION; CLINICAL TRIAL; CORRELATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HUMAN; LAPAROSCOPIC SURGERY; MATHEMATICAL COMPUTING; MULTIPLE REGRESSION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SIMULATION; STATISTICAL SIGNIFICANCE; VAGINAL HYSTERECTOMY;

COST-BENEFIT ANALYSIS; FEMALE; GREAT BRITAIN; HUMANS; HYSTERECTOMY; LAPAROSCOPY; MODELS, ECONOMETRIC; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS; REGRESSION ANALYSIS;

EID: 19444368977     PISSN: 10579230     EISSN: None     Source Type: Journal    
DOI: 10.1002/hec.944     Document Type: Article

References (46)

1. Manca A, Sculpher MJ, Ward K, Hilton P. A cost-utility analysis of tension-free vaginal tape versus colposuspension for primary urodynamic stress incontinence. BJOG: Int J Obstetr Gynaecol 2003; 110: 255-262.
2. The MRC Laparoscopic Groin Hernia Trial Group. Cost-utility analysis of open versus laparoscopic groin hernia repair: results from a multicentre randomised clinical trial. Br J Surg 2001; 88: 653-661.
3. Gilbert FJ, Grant AM, Gillan MG, Vale LD, Campbell MK, Scott NW et al. Low back pain: influence of early MR imaging or CT on treatment and outcome - multicenter randomized trial. Radiology 2004; 231: 343-351.
4. Lawrence K, McWhinnie D, Goodwin A et al. Randomised controlled trial of laparoscopic versus open repair of inguinal hernia: early results. Br Med J 1995; 311: 981-985.
5. Goossens MEJB, Rutten-van Molken MPMH, Leidl RM, Bos SGPM, Vlaeyen JWS, TeekenGruben NJ. Cognitive-educational treatment of fibromyalgia: a randomized clinical trial II economic evaluation. J Rheumato 1996; 23: 1246-1254.
6. Patrick DL, Ramsey SD, Spencer AC, Kinne S, Belza B, Topolski TD. Economic evaluation of aquatic exercise for persons with ostcoarthritis. Med Care 2001; 39: 413-424.
7. Health Technology Assessment. 2003. Available from: http://www.hta.nhsweb.nhs.uk. [cited]
8. Bryan S, Weatherburn G, Bungay H et al. The cost-effectiveness of magnetic resonance imaging for investigation of the knee joint. Health Technol Assess 2001; 5: 1-100.
9. Kennedy ADM, Sculpher MJ, Coulter A, Dwyer N, Rees M, Horsley S. A multicentre randomised controlled trial assessing the costs and benefits of using structured information and analysis of women's preferences in the management of menorrhagia. Health Technol Assess 2003; 7: 1-91.
10. King M, Sibbald B, Ward E et al. Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy and usual general practitioner care in the management of depression as well as mixed anxiety and depression in primary care. Health Technol Assess 2000; 4: 1-93.
11. Kendrick D, Fielding K, Bentley E, Miller P, Kerslake R, Pringle M. The role of radiography in primary care patients with low back pain of at least 6 weeks duration: a randomised (unblinded) controlled trial. Health Technol Assess 2001; 5: 1-77.
12. Allsup S, Gosney M, Haycox A, Regan M. Cost-benefit evaluation of routine influenza immunisation in people 65-74 years of age. Health Technol Assess 2003; 7: 1-92.
13. Pocock S, Assmann SE, Enos LE, Kasten LE. Subgroups analysis, covariate adjustment and baseline comparisons in clinical trials reporting: current practice and problems. Stat Med 2002; 21: 2917-2930.
14. Richardson G, Manca A. Calculation of Quality Adjusted Life Years (QALYs) in the published literature: a review of methodology and transparency. Health Econ 5 April 2004; DOI:10.1002 /hec.901.
15. Shen LZ, Pulkstenis E, Hoseyni M. Estimation of mean quality adjusted survival time. Stat Med 1999; 18: 1541-1554.
16. Zhao H, Tsiatis AA. A consistent estimator for the distribution of quality adjusted survival time. Biometrika 1997; 84: 339-348.
17. Willan AR, Lin DY, Cook RJ, Chen EB. Using inverse-weighting in cost-effectiveness analysis with censored data. Stat Methods Med Res 2002; 11: 539-551.
18. Billingham LJ, Abrams KR, Jones DR. Methods for the analysis of quality-of-life and survival data in health technology assessement. Health Technol Assess 1999; 3: 1-152.
19. Matthews JNS, Altman D, Campbell MJ. Analysis of serial measurements in medical research. Br Med J 1990; 300: 230-235.
20. Hurskainen R, Teperi J, Rissanen P et al. Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial. Lancet 2001; 357: 273-277.
21. Guthrie E, Moorey J, Margison F et al. Cost-effectiveness of brief psychodynamic-interpersonal therapy in high utilizers of psychiatric services. Arch General Psychiat 1999; 56: 519-526.
22. Cheng AK, Rubin HR, Powe N, Mellon NK, Francis HW, Niparko JK. Cost-utility analysis of the cochlear implant in children. J Am Med Assoc 2000; 284: 850-856.
23. Lumsden MA, Twaddle S, Hawthorn R et al. Randomised comparison and economic evaluation of laparoscopic assisted hysterectomy and abdominal hysterectomy. Br J Obstetr Gynaecol 2000; 107: 1386-1391.
24. Vickers AJ, Altman DG. Analysing controlled trials with baseline and follow up measurements. Br Med J 2001; 323: 1123-1124.
25. Vickers AJ. The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study. BMC Med Res Methodol 2001; 1: 16.
26. Garry R, Hawe J, Abbott J et al. The EVALUATE study: randomised trials comparing laparoscopic with abdominal and vaginal hysterectomy. Br Med J 2004; 328: 129-135.
27. Sculpher M, Manca A, Abbott J, Fountain J, Mason S, Garry R. The cost-effectiveness of laparoscopic-assisted hysterectomy in comparison with standard hysterectomy: The EVALUATE trial. Br Med J 2004; 328: 134-139.
28. Lin DY. Linear regression analysis of censored medical costs. Biostatistics 2000; 1: 35-47.
29. Efron B, Tibshirani R. An Introduction to the Bootstrap. Chapman & Hall: New York, 1993.
30. Barber JA, Thompson SG. Analysis of cost data in randomised controlled trials: An application of the non-parametric bootstrap. Stat Med 2000; 19: 3219-3236.
31. R Development Core Team. R: A language and environment for statistical computing. Version. 1.6, Vienna, Austria: R Foundation for Statistical Computing; 2004. Available from: http://www.R-project.org.
32. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps; a non-parametric approach to confidence interval estimation. Health Econ 1997; 6: 327-340.
33. Chaudhary MA, Stearns SC. Confidence intervals for cost-effectiveness ratios: An example from a randomized trial. Stat Med 1996; 15: 1447-1458.
34. Manning WG, Fryback DG, Weinstein MC. Reflecting uncertainty in cost-effectiveness analysis. In Cost-Effectiveness in Health and Medicine, Gold MR, Siegel JE, Russell LB, Weinstein MC (eds). Oxford University Press: New York, 1996.
35. Mullahy J. What you don't know can't hurt you? Statistical issues and standards for medical technology evaluation. Med Care 1996; 34: DS124-DS135.
36. Mullahy J, Manning W. Statistical issues of cost-effectiveness analysis. In Valuing Health Care, Sloan FA (ed.). Cambridge University Press: Cambridge, 1994.
37. O'Brien BJ, Drummond MF, Labelle RJ, Willan AR. In search of power and significance: Issues in the design and analysis of stochastic cost-effectiveness studies in heath care. Med Care 1994; 32: 150-163.
38. Polsky D, Glick HA, Willke R, Schulman K. Confidence intervals for cost-effectiveness ratios: A comparison of four methods. Health Econ 1997; 6: 243-252.
39. Van Hout BA, Al MJ, Gordon GS, Rutten FFH. Costs, effects and c/e-ratios alongside a clinical trial. Health Econ 1994; 3: 309-319.
40. Wakker P, Klaassen MP. Confidence intervals for cost/effectiveness ratios. Health Econ 1995; 4: 373-381.
41. Willan AR, O'Brien BJ. Confidence intervals for cost-effectiveness ratios: an application of Fiellers' theorem. Health Econ 1996; 5: 297-305.
42. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999; 18: 342-364.
43. Claxton K, Sculpher M, Drummond M. A rational framework for decision making by the National Institute for Clinical Excellence. Lancet 2002; 360: 711-715.
44. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001; 10: 779-789.
45. Willan AR, Briggs AH, Hoch JS. Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. Health Econ 2004; 13: 461-475.
46. Hoch JS, Briggs AH, Willan A. Something old, something new, something borrowed, something BLUE: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ 2002; 11: 415-430.